Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 292, Issue 3, pp 289–293 | Cite as

Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines

Relationship to drug induced parkinsonism
  • R. J. Miller
  • C. R. Hiley
Article

Summary

  1. 1.

    The anti-dopaminergic effects of several dibenzodiazepines were examined on the dopaminestimulated adenylate cyclase in rat striatal homogenates. The “cis” isomer of clozapine, HF-2046, was the most potent in this respect and perlapine, which is devoid of neuroleptic activity, was the weakest.

     
  2. 2.

    The anti-muscarinic effects of the same compounds were measured by using the muscarinic affinity label 3H-propylbenzilylcholine mustard. HF-2046 was the most potent and loxapine the least potent of the drugs used.

     
  3. 3.

    The anti-dopaminrgic effects of the drugs correlate well with neuroleptic but not with extrapyramidal effects. The anti-dopaminergic/anti-muscarinic ratio, however, correlates well with extrapyramidal rather than neuroleptic effects.

     

Key words

Clozapine Dibenzodiazepines Dopamine Muscarinic receptors Parkinsonism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andén, N.-E., Stock, G.: Effects of clozapine on turnover of dopamine in the corpus striatum and in the limbic system. J. Pharm. Pharmacol. 25, 346–348 (1973)Google Scholar
  2. Brown, B. C., Ekins, R. D., Albano, J. D. M.: Saturation assay for cyclic AMP using endogenous binding protein. In: Advances in cyclic nucleotide research vol. 2, P. Greengard and G. A. Robinson, eds., pp. 25–40. New York: Raven Press 1972Google Scholar
  3. Burgen, A. S. V., Hiley, C. R., Young, J. M.: The properties of muscarinic receptors in mammalian cerebral cortex. Brit. J. Pharmacol. 51, 279–285 (1974)Google Scholar
  4. Burki, H. R., Ruch, W., Asper, H., Baggiolini, M., Stille, G.: Pharmakologische und neurochemische Wirkungen von Clozapine; Neue Gesichtspunkte in der medikamentösen Behandlung. Schweiz. med. Wschr. 103, 1712–1724 (1973)Google Scholar
  5. Clement-Cormier, Y. C., Kebabian, J. W., Petzold, G. L., Greengard, P.: Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc. nat. Acad. Sci. (Wash.) 71, 1113–1117 (1974)Google Scholar
  6. Cole, J., Clyde, D. J.: Extrapyramidal side effects and clinical response to the phenothiazines. Rev. Canad. Biol. 20, 565–574 (1961)Google Scholar
  7. Horn, A. S., Snyder, S. H.: Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of the phenothiazines. Proc. nat. Acad. Sci. (Wash.) 68, 2325–2328 (1971)Google Scholar
  8. Hornykiewicz, O.: Parkinsonism induced by dopaminergic antagonists. In: Advances in neurology, vol. 5, D. B. Calne, T. N. Chase and A. Barbeau, eds., pp. 155–165. New York: Raven Press 1975Google Scholar
  9. Karobath, M., Leitich, H.: Antipsychotic drugs and dopamine-sensitive adenylate cyclase prepared from corpus striatum of rat brain. Proc. nat. Acad. Sci. (Wash.) 71, 2915–2918 (1974)Google Scholar
  10. Kebabian, J. W., Petzold, G. L., Greengard, P.: Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”. Proc. nat. Acad. Sci. (Wash.) 69, 2145–2149 (1972)Google Scholar
  11. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the Folin phenol reagent. J. biol. Chem. 193, 265–275 (1951)Google Scholar
  12. Miller, R. J., Hiley, C. R.: Antimuscarinic properties of neuroleptics and drug induced parkinsonism. Nature (Lond.) 248, 569–597 (1974)Google Scholar
  13. Miller, R. J., Horn, A. S., Iversen, L. L.: The action of neuroleptic drugs on dopamine stimulated adenosine-3′,5′-monophosphate production in rat neostriatum and limbic fore-brain. Molec. Pharmacol. 10, 759–765 (1974b)Google Scholar
  14. Miller, R. J., Horn, A. S., Iversen, L. L., Pinder, R. M.: Effects of dopamine like drugs on striatal adenylate cyclase: Implications for CNS dopamine receptor topography. Nature (Lond.) 250, 238–240 (1974a)Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • R. J. Miller
    • 1
  • C. R. Hiley
    • 2
  1. 1.M. R. C. Neurochemical Pharmacology Unit, Department of PharmacologyMedical SchoolCambridgeUK
  2. 2.Department of Pharmacology and TherapeuticsUniversity of LiverpoolLiverpoolUK

Personalised recommendations